Recall Record

Gurnee, IL, United States

Akorn, Inc. recalls

46 recalls recorded since 2018, most recently on 26 April 2023. 6 are listed as ongoing. Status and classification are as published by the FDA.

Recalls46
Ongoing (FDA)6
Terminated or completed40
Class I (FDA)0

Ongoing Class II Drugs

Recall started
26 April 2023
Reason
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall numbers
D-0818-2023, D-0794-2023, D-0820-2023, D-0864-2023, D-0790-2023, D-0844-2023, D-0787-2023, D-0817-2023, D-0792-2023, D-0786-2023, D-0821-2023, D-0827-2023 and 74 more

Ongoing Class III Drugs

Recall started
30 January 2023
Reason
Failed Stability Specifications: Out of specification test results for viscosity was identified at the 12M stability timepoint.
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0265-2023

Ongoing Class II Drugs

Recall started
13 October 2022
Reason
CGMP Deviations:
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-0158-2023, D-0143-2023, D-0146-2023, D-0140-2023, D-0142-2023, D-0141-2023, D-0157-2023, D-0149-2023, D-0155-2023, D-0151-2023, D-0139-2023, D-0135-2023 and 15 more

Ongoing Class II Drugs

Recall started
21 September 2022
Reason
Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).
Distribution
USA Nationwide and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall numbers
D-1547-2022, D-1548-2022

Terminated Class II Drugs

Recall started
31 August 2022
Terminated
18 June 2024
Reason
cGMP Deviations: Turbidity discovered in Artificial Tears Ointment during sterility testing. Scope expanded to include other lots and products which potentially share the same root cause.
Distribution
USA nationwide
Initiated
Voluntary: Firm initiated
Recall numbers
D-1495-2022, D-1496-2022

Ongoing Class III Drugs

Recall started
8 August 2022
Reason
Failed Impurities/Degradation Specifications: Identification of an unknown impurity at the 12-month stability point.
Distribution
Distributed Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-1471-2022

Ongoing Class II Drugs

Recall started
1 August 2022
Reason
Defective Container: Product has incomplete induction seals.
Distribution
Nationwide USA
Initiated
Voluntary: Firm initiated
Recall number
D-1361-2022

Terminated Class II Drugs

Recall started
13 June 2022
Terminated
14 July 2024
Reason
Defective container: defect prevents product from dispensing as intended.
Distribution
Nationwide USA
Initiated
Voluntary: Firm initiated
Recall number
D-1172-2022

Terminated Class II Drugs

Recall started
10 June 2022
Terminated
28 September 2023
Reason
Defective Delivery System: Potential defect that could prevent the product from dispensing as intended.
Distribution
Nationwide in the U.S.
Initiated
Voluntary: Firm initiated
Recall number
D-1170-2022

Terminated Class III Drugs

Recall started
15 April 2022
Terminated
28 September 2023
Reason
Failed viscosity specification - product was below specificcation
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0846-2022

Terminated Class II Drugs

Recall started
5 January 2022
Terminated
17 September 2022
Reason
Subpotent Drug: Out of specification for assay at the 30-month stability timepoint.
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0460-2022

Terminated Class III Drugs

Recall started
3 December 2021
Terminated
19 August 2022
Reason
Labeling: Missing Label
Distribution
Nationwide USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-0367-2022, D-0368-2022

Terminated Class II Drugs

Recall started
4 October 2021
Terminated
17 August 2022
Reason
Microbial Contamination of Sterile Products: Confirmed sterility failure identified during stability testing at the 12-month time point.
Distribution
Distributed Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0004-2022

Terminated Class II Drugs

Recall started
8 September 2021
Terminated
28 September 2023
Reason
Lack of Assurance of Sterility
Distribution
Nationwide within theUSA
Initiated
Voluntary: Firm initiated
Recall number
D-0717-2022

Terminated Class II Drugs

Recall started
13 August 2021
Terminated
17 August 2022
Reason
Failed impurities/degradation specification: Out of Specification for an unknown impurity observed in topical product.
Distribution
USA Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0802-2021

Terminated Class II Drugs

Recall started
2 August 2021
Terminated
22 August 2022
Reason
Non-Sterility - OOS sterility testing observed during 12-month controlled room temperature stability testing. The microbiological investigation identified the organism as a member of the Bacillus cereus group.
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0786-2021

Terminated Class II Drugs

Recall started
8 March 2021
Terminated
9 August 2022
Reason
Failed Impurities/Degradation Specifications; out of specification for unknown impurity observed during 6 month stability testing
Distribution
Nationwide USA
Initiated
Voluntary: Firm initiated
Recall number
D-0301-2021

Terminated Class II Drugs

Recall started
28 December 2020
Terminated
9 August 2022
Reason
Defective container: Customer complaints for oral solution leaking from bottles.
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0221-2021

Terminated Class II Drugs

Recall started
3 September 2020
Terminated
1 August 2022
Reason
CGMP Deviations
Distribution
Nationwide in CA, IN, VA, NJ, NY, RI, FL, TX, MO, PA, MI, AL, TN, SC
Initiated
Voluntary: Firm initiated
Recall number
D-1628-2020

Terminated Class III Drugs

Recall started
5 June 2020
Terminated
28 July 2022
Reason
Discoloration: Out of Specification (OOS) result for APHA Color Test.
Distribution
Distributed Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-1340-2020

Terminated Class III Drugs

Recall started
25 March 2020
Terminated
28 July 2022
Reason
Failed impurities/degradation specification: Out-of-Specification result for total impurity at 4.1% (Limit: NMT 3.0%) during retained sample testing.
Distribution
Distributed Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-1258-2020

Terminated Class III Drugs

Recall started
21 February 2020
Terminated
28 July 2022
Reason
Presence of Particulate Matter: Brown spots observed on the inside of the tube of product, identified as tin with trace copper, which are the base of the materials of construction for the tube.
Distribution
Nationwide within United States and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall numbers
D-0860-2020, D-0861-2020, D-0859-2020

Terminated Class III Drugs

Recall started
26 December 2019
Terminated
28 July 2022
Reason
Chemical contamination; out of specification results obtained for equipment cleaning residue rinse sample
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-1388-2020

Terminated Class II Drugs

Recall started
16 December 2019
Terminated
29 July 2022
Reason
Subpotent Drug: Low Out of specification (OOS) assay results for the hydrocortisone portion of this product.
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0839-2020

Terminated Class II Drugs

Recall started
15 November 2019
Terminated
9 August 2022
Reason
Unit Dose Mispackaging: Customer complaint that a carton labeled as Myorisan 20 mg Capsules, USP erroneously contained one 10-count blister card of the 40 mg product in addition to two 10-count blister cards of the 20 mg product.
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0647-2020

Terminated Class II Drugs

Recall started
20 September 2019
Terminated
1 August 2022
Reason
Lack of Assurance of Sterility: Out of specification results for container closure test which cannot guarantee the sterility of the product.
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-1883-2019

Terminated Class II Drugs

Recall started
17 September 2019
Terminated
1 August 2022
Reason
cGMP Deviations: firm reported finding metal particulate matter in the filling room near the tube feeder during the filling operation of the product. No particulates were identified in the product, but rather were identified on the filling line.
Distribution
Nationwide within the United States and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-1878-2019

Terminated Class III Drugs

Recall started
6 August 2019
Terminated
28 July 2022
Reason
Failed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid.
Distribution
Nationwide in the U.S.
Initiated
Voluntary: Firm initiated
Recall numbers
D-1839-2019, D-1841-2019, D-1840-2019

Terminated Class III Drugs

Recall started
7 June 2019
Terminated
28 July 2022
Reason
Labeling: Label mix-up: Product secondary carton erroneously states 40mg instead of 30 mg, primary carton is label correctly.
Distribution
Nationwide USA
Initiated
Voluntary: Firm initiated
Recall number
D-1392-2019

Terminated Class III Drugs

Recall started
23 April 2019
Terminated
28 July 2022
Reason
Failed impurities/degradation specification: Out of Specification result for total impurity at 4.0% (Limit: NMT 3.0%) at 12 months stability testing.
Distribution
U.S.A. Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-1241-2019

Terminated Class III Drugs

Recall started
28 March 2019
Terminated
22 April 2020
Reason
Failed Impurities/Degradation Specifications: Out of Specification for an unknown impurity was observed during the 18 month stability testing.
Distribution
AR and MS
Initiated
Voluntary: Firm initiated
Recall number
D-1080-2019

Terminated Class II Drugs

Recall started
12 March 2019
Terminated
1 August 2022
Reason
Sub Potent Drug: OOS results observed for the Hydrocortisone assay during routine stability testing at 12 month controlled room temperature.
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-1011-2019

Terminated Class II Drugs

Recall started
22 February 2019
Terminated
9 August 2022
Reason
Failed Impurities/Degradation Specifications: High Out-of-Specification (OOS) results for Individual and Total Impurities that have been identified at the 18 months stability testing time point.
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0993-2019

Terminated Class II Drugs

Recall started
4 February 2019
Terminated
29 July 2022
Reason
Failed Stability Specification: out of specification results for Sodium Perborate
Distribution
Nationwide in the USA.
Recall number
D-0511-2019

Terminated Class III Drugs

Recall started
25 January 2019
Terminated
3 November 2020
Reason
Failed Stability Specification; out of specification (OOS) results for a preservative at 9 month stability study.
Distribution
Nationwide, including Puerto Rico.
Initiated
Voluntary: Firm initiated
Recall number
D-0515-2019

Terminated Class III Drugs

Recall started
20 December 2018
Terminated
6 November 2020
Reason
Failed Stability Specifications: out of specification results for opalescence at 7 month stability study.
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0483-2019

Terminated Class III Drugs

Recall started
29 October 2018
Terminated
9 August 2022
Reason
Failed Impurities/Degradation Specifications; out of specification results observed for other individual impurities
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-1208-2019

Terminated Class II Drugs

Recall started
8 October 2018
Terminated
15 June 2022
Reason
Presence of Particulate Matter: Crystalline particles were noticed at the 24 month clarity testing.
Distribution
Nationwide USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0414-2019

Terminated Class II Drugs

Recall started
24 August 2018
Terminated
6 November 2020
Reason
Failed Impurities/Degradation Specifications: Out of specification (OOS) results for unspecified impurity.
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-1183-2018

Terminated Class III Drugs

Recall started
8 August 2018
Terminated
3 November 2020
Reason
Failed Impurities/Degradation Specifications:out-of-specification (OOS) results for Azelastine N-oxide
Distribution
Nationwide USA
Initiated
Voluntary: Firm initiated
Recall number
D-1168-2018

Terminated Class II Drugs

Recall started
1 August 2018
Terminated
6 November 2020
Reason
Failed Impurities/Degredation Specifications: Out of Specification results for an unknown impurity was found during routine stability testing at 12 months.
Distribution
Nationwide within the USA
Initiated
Voluntary: Firm initiated
Recall number
D-1046-2018

Terminated Class II Drugs

Recall started
22 June 2018
Terminated
6 November 2020
Reason
CGMP Deviations
Distribution
U.S. Nationwide
Recall number
D-0916-2018

Terminated Class III Drugs

Recall started
29 March 2018
Terminated
22 April 2020
Reason
Subpotent Drug: Product crystallization with accompanying low out of specification results for chlorhexidine assay.
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-0612-2018, D-0613-2018, D-0611-2018

Terminated Class III Drugs

Recall started
9 March 2018
Terminated
31 August 2020
Reason
Failed Impurities/Degradation Specifications: High out of specification results for an impurity.
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0617-2018

Terminated Class III Drugs

Recall started
21 February 2018
Terminated
31 August 2020
Reason
Failed Stability Specification: OOS low viscosity results discovered during retain testing.
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0577-2018

Terminated Class III Drugs

Recall started
15 December 2017
Terminated
10 April 2019
Reason
CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0211-2018

A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.